While BPC-157 has an excellent safety profile, doses above 500 mcg daily provide diminishing returns and increase cost without proportional benefits
(5) M V Graf, A J Kastin, D H Coy, and A J Fischman (1985) Delta-sleep-inducing peptide reduces CRF-induced corticosterone release Neuroendocrinology, 1985 Oct, Volume 41 (Issue 4), Pages 353-6
Side Effects & Safety AOD-9604 has a genuinely clean safety profile based on both clinical studies and community use: Injection site reactions: Mild redness or bruising, common and temporary Headache: Reported by a minority of users in the first week, typically self-resolving Fatigue: Occasional, especially at higher doses usually resolves No significant hormonal disruption: Unlike full HGH, no thyroid, insulin, or IGF-1 concerns at standard doses AOD-9604 received GRAS (Generally Recognized As Safe) status from the FDA for use as a food ingredient during its development phase an unusual distinction that reflects its clean clinical safety data
The ratio between oxidized and reduced glutathione in the body is an indicator of oxidative stress and cellular health
